Skip to main content
← Companies
DVAX

DYNAVAX TECHNOLOGIES CORP

Data as of Sep 17, 2026
DVAX
CIK 1029142

Lobbying

$1,385,000 in reported federal lobbying spend across 14 quarterly filings, most recently Jul 20, 2026. Amounts are the sums companies and their registrants report on Lobbying Disclosure Act filings; a filing that covers several issues counts its full amount under each.

Spend by issue

  • Pharmacy$525K7 filings

Latest filings, Jan 2026 onward

FiledRegistrant and subjectAmount
Jul 20, 2026
RUBICON ADVISORS, LLC for DYNAVAX TECHNOLOGIES
Pharmacy Prescription User Fee, Biomedical Advance Research and Development Authority (BARDA)
$75,000
Jul 17, 2026
DYNAVAX TECHNOLOGIES CORP.
Unspecified
$120,000
Apr 23, 2026
RUBICON ADVISORS, LLC for DYNAVAX TECHNOLOGIES
Pharmacy Prescription User Fee, Biomedical Advance Research and Development Authority (BARDA)
$75,000
Apr 20, 2026
DYNAVAX TECHNOLOGIES CORP.
Unspecified
$120,000
Jan 18, 2026
RUBICON ADVISORS, LLC for DYNAVAX TECHNOLOGIES
Pharmacy Prescription User Fee, Biomedical Advance Research and Development Authority (BARDA)
$75,000
Jan 17, 2026
DYNAVAX TECHNOLOGIES CORP.
Unspecified
$120,000

Data: Quiver Quantitative, FEC, Senate Lobbying Disclosure Act filings, USAspending, congressional periodic transaction reports. Records are matched to DYNAVAX TECHNOLOGIES CORP through its SEC registration (CIK 1029142) and tickers DVAX.

As of: lobbying filings through Jul 20, 2026; contract actions through Sep 22, 2025. Snapshot rebuilt Sep 17, 2026.

Holdings values are estimates from disclosed ranges. Donation coverage for a cycle begins with the first month loaded, so earlier months may still be missing.